The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...
Novartis’ immunology drug Cosentyx (secukinumab) notched its sixth indication, gaining U.S. approval as a hidradenitis suppurativa (HS) therapy, the drugmaker said this week. The regulatory OK makes ...
New data suggests that disease modification with Cosentyx may be achievable for around 20% of patients following one year of treatment[1] Patients with longer disease duration before treatment with ...
Psoriasis is not simply a cosmetic problem, but a persistent, chronic (long-lasting), and sometimes distressing disease, which can affect even the smallest aspects of people`s lives on a daily ...
The 2025 European Academy of Dermatology and Venereology (2025 EADV), the largest dermatology conference in Europe, opened on the 17th (local time) in Paris, France. Running through the 20th, EADV ...
Cosentyx may soon share the hidradenitis suppurativa (HS) field with another inflammatory biologic—but, for now, the Novartis drug has a head start. That’s good news for the Swiss Pharma, given that ...
Novartis’ psoriasis drug, Cosentyx (secukinumab) received a boost after data showed it is better at clearing skin than Johnson & Johnson’s rival Stelara. Cosentyx is one of several newer drugs that ...
Novartis’ Cosentyx has a head start on the next-gen psoriasis pack, but the company is still gunning to build its lead before a raft of new competitors arrive. And now, the Swiss drugmaker has some ...
Novartis has presented new data showing that its biologic Cosentyx reduced signs and symptoms of psoriatic arthritis (PsA) while inhibiting progression of joint structural damage. Novartis has ...
Cosentyx (secukinumab) may be safe to use while pregnant or breastfeeding. Before starting treatment, you and your doctor can discuss the risks and benefits of Cosentyx treatment during pregnancy or ...
Find out what Novartis' pipeline strategy since it spun off its biosimilars and generics business Sandoz, and engage in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results